Supplemental Table 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

crossref(2024)

引用 0|浏览2
暂无评分
摘要

Supplemental Table 3: Overall response rate and complete remission rate by venetoclax dose and schedule.

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要